{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-061954","form_type":"8-K","ticker":"HYPD","cik":"0001682639","company_name":"HYPERION DEFI, INC.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.572128+00:00","generated_at":"2026-06-01T23:18:50.721205+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eyenovia Q1 net loss $10.9M, up from $5.7M; advances MicroPine and clobetasol pipeline","bullets":["Net loss Q1 2024 $10.9M ($0.23/shr) vs $5.7M ($0.15/shr) in Q1 2023; includes $2.5M charge for MicroPine license reacquisition.","R&D expenses $4.4M (+75.7% YoY), G&A $3.8M (+30.6% YoY); total operating expenses $10.3M (+88.1% YoY).","Cash and equivalents $8.0M at March 31, 2024; additional $2.2M raised in April 2024.","MicroPine Phase 3 CHAPERONE DMC review planned for early Q4 2024; clobetasol launch targeted for Q3 2024.","Mydcombi rollout: 50 new offices trained; reduced cash expenses by ~$0.8M per quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-061954","json":"https://secwatch.observer/filing/0001104659-24-061954.json","markdown":"https://secwatch.observer/filing/0001104659-24-061954.md","text":"https://secwatch.observer/filing/0001104659-24-061954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682639/000110465924061954/0001104659-24-061954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682639/000110465924061954/tm2414361d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:18:50.721205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b72aaf82489654889754695ac0f0bfa65ee91b29","claim":"HYPERION DEFI, INC. reported the first quarter ended March 31, 2024 results: net income net loss was approximately $10.9 million, EPS $0.23 per share.","evidence_excerpt":"For the first quarter of 2024, net loss was approximately $10.9 million, or $0.23 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682639/000110465924061954/0001104659-24-061954-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"net loss was approximately $10.9 million"},{"label":"EPS","value":"$0.23 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}